Dr. Reddy’s Laboratories relaunches OTC Naproxen Sodium Tablets in US

Dr. Reddy’s Laboratories said that it has relaunched over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Bayer HealthCare’s Aleve, in the US market.

The relaunch is as per the approval from the US Food and Drug Administration (FDA), said the Indian pharma company.

According to Dr. Reddy’s Laboratories, its OTC Naproxen Sodium Tablets USP, 220 mg is a nonsteroidal anti-inflammatory drug (NSAID) to be used for relieving pain and reducing fever. It temporarily alleviates minor aches and pains caused by minor pain of arthritis, backache, muscular aches, headache, menstrual cramps, toothache, and the common cold.

As per IRI, Naproxen Sodium Tablets USP, 220 mg, had nearly $316 million in retail sales in the US, as of July 2021.

Dr. Reddy’s Laboratories relaunches OTC Naproxen Sodium Tablets in US. Photo courtesy of Karthikndr/Wikimedia Commons.

Dr. Reddy’s Laboratories said that its Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to give a range of buying options for consumers.

Marc Kikuchi — CEO of Dr. Reddy’s Laboratories North America Generics said: “The re-launch of Dr. Reddy’s Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products.

“This launch represents our continued endeavor to leverage our strong capabilities and vertically integrated supply chain on key APls like naproxen to ensure a consistent and reliable supply of finished products for our customers and patients.”